P0201Sleep Quality in Patients with Inflammatory Bowel Disease

Background Sleep disturbances are increasingly recognized as a significant comorbidity in inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, affecting disease activity, fatigue, gastrointestinal symptoms, mood, and quality of life. Prospective longitudinal data remain limited. Methods This one-year prospective single-center study included 76 consecutive IBD patients; (mean age 40 years; 62% female) enrolled between November 2024 and November 2025. Inclusion criteria were age ≥18 years, confirmed IBD, and stable maintenance therapy ≥3 months; patients with primary sleep disorders, major psychiatric comorbidities, or recent surgery were excluded. Sleep quality was assessed every six months using the Pittsburgh Sleep Quality Index (PSQI), with additional evaluation of sleep latency, total sleep time, nocturnal awakenings, insomnia symptoms, and fragmentation. Clinical disease activity was measured using CDAI and partial Mayo score; biochemical markers included CRP, fecal calprotectin, hemoglobin, ferritin, and albumin. Patient-centered outcomes included quality of life (IBDQ, SF-36), fatigue (VAS), gastrointestinal symptoms, flare frequency, hospitalizations, self-perceived health, and work productivity. Results At baseline, mean PSQI was 7.6, with 62% of patients exhibiting impaired sleep. Insomnia was reported in 48%, nocturnal awakenings in 42%, and fragmented sleep in 35%. Active disease was associated with worse sleep (PSQI 9.3 vs. 5.9, p < 0.01), elevated CRP and fecal calprotectin, and lower hemoglobin, ferritin, and albumin. Poor sleep correlated with lower IBDQ (155 vs. 185) and SF-36 scores, higher fatigue (VAS 6.8 vs. 3.9), more severe gastrointestinal symptoms (4.2 vs. 2.1), increased flare frequency (1.8 vs. 0.9/year), hospitalizations (0.7 vs. 0.3/year), lower self-perceived health (VAS 6.2 vs. 8.4), and reduced work productivity (3.6 vs. 1.2 h/week; all p < 0.05). Longitudinal analyses showed sleep quality improved with disease remission, paralleling reductions in inflammation, fatigue, and gastrointestinal symptoms. PSQI scores strongly correlated with patient-centered outcomes (r = 0.45–0.62, p < 0.01). Conclusion In conclusion, sleep disturbances are common and closely linked to clinical and patient-centered outcomes in IBD. Routine sleep assessment and targeted interventions may represent a modifiable factor to optimize wellbeing. Future multicenter studies should confirm these findings and evaluate sleep-focused interventions. Conflict of interest: Prof. Dr. Aouroud, Meryem: No conflict of interest Aouroud, Hala: No conflict of interest Nacir, Oussama: No conflict of interest Lairani, Fatima ezzahra: No conflict of interest Ait errami, Adil: No conflict of interest Oubaha, Sofia: No conflict of interest Samlani, Zouhour: No conflict of interest Krati, Khadija: No conflict of interest